[169Yb-dichlorodimethionine platinum (II) as a tumor-seeking radiopharmaceutical].
Biodistribution studies of 169Yb-dichlorodimethioninoplatin (II) in mice, bearing Ehrlich or leukemia tumors, showed increased uptake of the complex in the tumors. A large difference in the retention of the total injected activity was found depending on the optical isomeric form of the methionine part of the complex.
D000818:Animals; D051379:Mice; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000378:metabolism; D011877:Radionuclide Imaging; D014018:Tissue Distribution; D015018:Ytterbium / Q000378:metabolism
D009944:Organoplatinum Compounds; C053621:ytterbium-dichlorodimethionine platinum(II); D015018:Ytterbium
169Yb-dichlorodimethioninoplatin (II) als tumoraffines Nuklearpharmakon.